205 related articles for article (PubMed ID: 28289895)
21. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.
Jiang Q; Gale RP
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1549-55. PubMed ID: 27085530
[TBL] [Abstract][Full Text] [Related]
22. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
23. Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
Al-Dewik NI; Morsi HM; Samara MM; Ghasoub RS; Gnanam CC; Bhaskaran SK; Nashwan AJ; Al-Jurf RM; Ismail MA; AlSharshani MM; AlSayab AA; Ben-Omran TI; Khatib RB; Yassin MA
Clin Med Insights Oncol; 2016; 10():95-104. PubMed ID: 27721664
[TBL] [Abstract][Full Text] [Related]
24. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.
Davis TC; Arnold CL; Mills G; Lesser GJ; Brown WM; Schulz R; Weaver KE; Pawloski PA
Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769563
[TBL] [Abstract][Full Text] [Related]
26. The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms.
Moulin SM; Eutrópio FJ; Souza JO; Busato FO; Olivieri DN; Tadokoro CE
Support Care Cancer; 2017 Mar; 25(3):951-955. PubMed ID: 27866336
[TBL] [Abstract][Full Text] [Related]
27. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies.
Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D
Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687
[TBL] [Abstract][Full Text] [Related]
28. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
29. Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.
Dicus M; Lyons B; Olson C; Tran DA; Blackburn DF
J Oncol Pharm Pract; 2015 Dec; 21(6):403-8. PubMed ID: 24903271
[TBL] [Abstract][Full Text] [Related]
30. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
[TBL] [Abstract][Full Text] [Related]
31. Educational session: managing chronic myeloid leukemia as a chronic disease.
Hochhaus A
Hematology Am Soc Hematol Educ Program; 2011; 2011():128-35. PubMed ID: 22160024
[TBL] [Abstract][Full Text] [Related]
32. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
33. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.
de la Fuente J; Baruchel A; Biondi A; de Bont E; Dresse MF; Suttorp M; Millot F;
Br J Haematol; 2014 Oct; 167(1):33-47. PubMed ID: 24976289
[TBL] [Abstract][Full Text] [Related]
34. Clinical pathway for patients with Chronic Myeloid Leukaemia: The Euriclea Project.
Botti S; Gargiulo G; Bombaci F; Artioli G; Cosentino C; Pignatelli AC; Torino D; Lionetti MM; Samarani E; Cappucciati L; Bordiga P; Diodati A; Caffarri C; Rosini I; Pane F
Acta Biomed; 2017 Jul; 88(3S):5-12. PubMed ID: 28752827
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
37. Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors.
Hefner J; Csef EJ; Kunzmann V
Oncol Nurs Forum; 2016 Mar; 43(2):190-7. PubMed ID: 26906130
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
39. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
Jiang Q; Liu ZC; Zhang SX; Gale RP
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
[TBL] [Abstract][Full Text] [Related]
40. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
